IFNA1 and coronary artery disorder: A phase 2 randomized clinical trial of 33 CHD [146] patients treated with Peg IFN-λ 180μg monotherapy for 48 weeks demonstrated 36% durable virologic response 24 weeks post-treatment compared to PEG IFN-α (28%).